Crinetics Pharmaceuticals (CRNX) Short Interest Ratio & Short Volume $32.33 -0.75 (-2.27%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$33.32 +0.98 (+3.05%) As of 09:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Crinetics Pharmaceuticals Short Interest DataCrinetics Pharmaceuticals (CRNX) has a short interest of 10.21 million shares, representing 11.71% of the float (the number of shares available for trading by the public). This marks a 0.49% increase in short interest from the previous month. The short interest ratio (days to cover) is 10.6, indicating that it would take 10.6 days of the average trading volume of 846,090 shares to cover all short positions.Current Short Interest10,210,000 sharesPrevious Short Interest10,160,000 sharesChange Vs. Previous Month+0.49%Dollar Volume Sold Short$312.32 millionShort Interest Ratio10.6 Days to CoverLast Record DateMay 31, 2025Outstanding Shares93,629,000 sharesShort Percent of Float11.71%Today's Trading Volume420,639 sharesAverage Trading Volume846,090 sharesToday's Volume Vs. Average50% Short Selling Crinetics Pharmaceuticals? Sign up to receive the latest short interest report for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCRNX Short Interest Over TimeCRNX Days to Cover Over TimeCRNX Percentage of Float Shorted Over Time Crinetics Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/202510,210,000 shares $312.32 million +0.5%11.7%10.6 $30.59 5/15/202510,160,000 shares $317.09 million +3.3%11.7%9.8 $31.21 4/30/20259,840,000 shares $328.56 million +2.2%N/A9.7 $33.39 4/15/20259,630,000 shares $285.63 million +12.8%11.0%9.6 $29.66 3/31/20258,540,000 shares $286.43 million +9.9%9.8%7.8 $33.54 3/15/20257,770,000 shares $267.83 million -4.2%8.9%7.9 $34.47 2/28/20258,110,000 shares $290.18 million +4.0%9.3%8.6 $35.78 2/15/20257,800,000 shares $274.64 million +5.7%8.9%9.1 $35.21 1/31/20257,380,000 shares $297.41 million +2.9%N/A8.7 $40.30 1/15/20257,170,000 shares $263.35 million +3.6%N/A8.9 $36.73 Get the Latest News and Ratings for CRNX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 12/31/20246,920,000 shares $353.82 million +10.7%N/A8.9 $51.13 12/15/20246,250,000 shares $335.38 million +4.0%N/A8.4 $53.66 11/30/20246,010,000 shares $343.77 million -7.5%N/A8.4 $57.20 11/15/20246,500,000 shares $355.68 million -6.3%N/A9.1 $54.72 10/31/20246,940,000 shares $388.36 million +5.3%N/A10.5 $55.96 10/15/20246,590,000 shares $379.58 million -2.8%N/A9.8 $57.60 9/30/20246,780,000 shares $346.46 million +11.0%N/A10.3 $51.10 9/15/20246,110,000 shares $328.72 million -1.8%N/A8.2 $53.80 8/31/20246,220,000 shares $330.03 million -3.9%N/A8.3 $53.06 8/15/20246,470,000 shares $339.87 million +5.7%N/A8 $52.53 7/31/20246,120,000 shares $325.09 million -7.0%N/A6.6 $53.12 7/15/20246,580,000 shares $356.24 million +12.1%N/A7 $54.14 6/30/20245,870,000 shares $262.92 million +0.2%N/A6.5 $44.79 6/15/20245,860,000 shares $265.63 million +16.5%N/A6.7 $45.33 5/31/20245,030,000 shares $223.38 million +2.4%N/A5.6 $44.41 5/15/20244,910,000 shares $247.91 million No ChangeN/A5.5 $50.49 4/30/20244,910,000 shares $215.16 million -5.9%N/A5.9 $43.82 4/15/20245,220,000 shares $228.01 million +6.3%N/A6.5 $43.68 3/31/20244,910,000 shares $229.84 million -2.0%N/A6.1 $46.81 3/15/20245,010,000 shares $195.04 million +5.7%N/A6.7 $38.93 2/29/20244,740,000 shares $194.06 million +5.1%N/A6 $40.94 2/15/20244,510,000 shares $166.51 million -11.1%N/A5.8 $36.92 1/31/20245,070,000 shares $184.95 million -0.8%N/A6.2 $36.48 1/15/20245,110,000 shares $190.04 million -0.6%N/A6 $37.19 12/31/20235,140,000 shares $182.88 million -13.6%N/A5.9 $35.58 12/15/20235,950,000 shares $205.04 million -6.7%N/A6.4 $34.46 11/30/20236,380,000 shares $202.82 million +2.9%N/A4 $31.79 11/15/20236,200,000 shares $179.06 million -7.6%N/A4 $28.88 10/31/20236,710,000 shares $196.54 million -1.5%N/A4.4 $29.29 10/15/20236,810,000 shares $198.24 million +16.4%N/A4.7 $29.11Trump wipes out trillions overnight… (Ad)Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.Whether you take some of that wealth for yourself depends on if you watch this controversial exposé 9/30/20235,850,000 shares $173.98 million +43.7%N/A4.1 $29.74 9/15/20234,070,000 shares $120.02 million -10.4%N/A3.1 $29.49 8/31/20234,540,000 shares $78.63 million +21.4%N/A5.2 $17.32 8/15/20233,740,000 shares $62.53 million +11.0%N/A7.9 $16.72 7/31/20233,370,000 shares $64.03 million -2.9%N/A7.2 $19.00 7/15/20233,470,000 shares $70.68 million +1.5%N/A7.2 $20.37 6/30/20233,420,000 shares $61.63 million +4.0%N/A7.6 $18.02 6/15/20233,290,000 shares $68.33 million No ChangeN/A7 $20.77 5/31/20233,290,000 shares $71.82 million -4.4%N/A7.2 $21.83 5/15/20233,440,000 shares $76.82 million -18.9%N/A7.7 $22.33 4/30/20234,240,000 shares $82.85 million -1.2%N/A9.9 $19.54 4/15/20234,290,000 shares $68.34 million -6.3%N/A10.6 $15.93 3/31/20234,580,000 shares $73.55 million +12.3%N/A10.8 $16.06 3/15/20234,080,000 shares $70.14 million +12.1%N/A10.1 $17.19 2/28/20233,640,000 shares $71.49 million +7.4%N/A8.9 $19.64 2/15/20233,390,000 shares $67.70 million -4.0%N/A8.8 $19.97 1/31/20233,530,000 shares $69.22 million -5.4%N/A9.3 $19.61 1/15/20233,730,000 shares $67.29 million No ChangeN/A11.1 $18.04 12/30/20223,730,000 shares $68.26 million +3.3%N/A11.7 $18.30 12/15/20223,610,000 shares $58.63 million -5.3%N/A12.1 $16.24 11/30/20223,810,000 shares $68.08 million -1.3%N/A14.3 $17.87 11/15/20223,860,000 shares $70.41 million -3.7%N/A14.3 $18.24 10/31/20224,010,000 shares $74.02 million -1.7%N/A14.4 $18.46 10/15/20224,080,000 shares $72.05 million +1.5%N/A15 $17.66 9/30/20224,020,000 shares $78.95 million +3.1%N/A15.6 $19.64 9/15/20223,900,000 shares $83.34 million +9.9%N/A14 $21.37 8/31/20223,550,000 shares $67.02 million +13.4%N/A12.3 $18.88 8/15/20223,130,000 shares $70.02 million +12.6%N/A10.3 $22.37 7/31/20222,780,000 shares $53.40 million -2.1%N/A8.9 $19.21 7/15/20222,840,000 shares $58.82 million -1.1%N/A9 $20.71 6/30/20222,870,000 shares $53.53 million +5.9%N/A8.3 $18.65 6/15/20222,710,000 shares $47.86 million +8.8%N/A7.4 $17.66 5/31/20222,490,000 shares $41.71 million +2.1%N/A7.5 $16.75 5/15/20222,440,000 shares $45.75 million +11.9%N/A7.9 $18.75 4/30/20222,180,000 shares $44.30 million -18.1%N/A7.9 $20.32 4/15/20222,660,000 shares $69.16 million +0.8%N/A9.5 $26.00 3/31/20222,640,000 shares $57.95 million +13.3%N/A10.7 $21.95 3/15/20222,330,000 shares $44.46 million +10.4%6.2%9.6 $19.08 2/28/20222,110,000 shares $42.24 million +0.5%5.6%8.1 $20.02 2/15/20222,100,000 shares $41.43 million +23.5%5.6%7.6 $19.73 1/31/20221,700,000 shares $32.11 million +39.3%N/A6.1 $18.89 1/15/20221,220,000 shares $29.29 million -6.9%N/A4.3 $24.01 12/31/20211,310,000 shares $37.22 million +12.0%N/A4.1 $28.41 12/15/20211,170,000 shares $29.45 million +18.1%N/A3.8 $25.17 11/30/2021990,900 shares $27.07 million -1.9%N/A3.6 $27.32 11/15/20211,010,000 shares $27.26 million -13.7%N/A3.8 $26.99 10/29/20211,170,000 shares $29.17 million -17.0%3.4%4.4 $24.93 10/15/20211,410,000 shares $27.48 million -4.7%4.8%5.7 $19.49 9/30/20211,480,000 shares $31.15 million +16.5%5.0%8.5 $21.05 9/15/20211,270,000 shares $29.85 million -3.1%4.3%6.7 $23.50Get Ready for Elon Musk’s BIGGEST Comeback Yet (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. Click here to see why Tesla's about to prove everyone wrong... again. 8/31/20211,310,000 shares $30.88 million +5.7%4.7%6.7 $23.57 8/13/20211,240,000 shares $27.60 million -4.6%4.4%6.3 $22.26 7/30/20211,300,000 shares $23.37 million -0.8%4.9%7.8 $17.98 7/15/20211,310,000 shares $25.82 million -3.7%4.5%8.2 $19.71 6/30/20211,360,000 shares $25.64 million +2.3%4.7%7.9 $18.85 6/15/20211,330,000 shares $24.25 million -8.3%4.6%7.9 $18.23 5/28/20211,450,000 shares $25.45 million -4.6%5.0%10.2 $17.55 5/14/20211,520,000 shares $24.17 million -0.7%N/A12 $15.90 4/30/20211,530,000 shares $27.17 million -0.7%N/A11.1 $17.76 4/15/20211,540,000 shares $25.29 million +2.0%N/A11.1 $16.42 3/31/20211,510,000 shares $23.31 million -2.6%N/A11 $15.44 3/15/20211,550,000 shares $26.24 million +1.3%N/A11.1 $16.93 2/26/20211,530,000 shares $23.03 million +10.9%N/A11.2 $15.05 2/12/20211,380,000 shares $23.78 million -7.4%N/A9 $17.23 1/29/20211,490,000 shares $22.22 million +2.1%N/A9.5 $14.91 1/15/20211,460,000 shares $21.58 million +1.4%N/A8.3 $14.78 12/31/20201,440,000 shares $19.71 million +9.9%N/A8.2 $13.69 12/15/20201,310,000 shares $17.99 million +0.8%N/A8.1 $13.73 11/30/20201,300,000 shares $18.67 million +3.2%N/A8.8 $14.36 11/15/20201,260,000 shares $16.23 million +7.7%N/A9.1 $12.88 10/30/20201,170,000 shares $14.60 million -14.6%N/A9.9 $12.48 10/15/20201,370,000 shares $22.15 million -3.5%N/A13.2 $16.17 9/30/20201,420,000 shares $22.25 million +2.2%N/A14.3 $15.67 9/15/20201,390,000 shares $22.27 million -3.5%N/A8.7 $16.02 8/31/20201,440,000 shares $23.08 million -0.7%N/A7.6 $16.03 8/14/20201,450,000 shares $22.05 million -2.7%N/A7.1 $15.21 7/31/20201,490,000 shares $20.68 million -15.8%N/A6.8 $13.88 7/15/20201,770,000 shares $26.92 million -30.3%N/A8.1 $15.21 6/30/20202,540,000 shares $45.42 million +84.1%10.6%10.4 $17.88 6/15/20201,380,000 shares $23.54 million No Change5.7%7.2 $17.06 CRNX Short Interest - Frequently Asked Questions What is Crinetics Pharmaceuticals' current short interest? Short interest is the volume of Crinetics Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of May 31st, traders have sold 10,210,000 shares of CRNX short. 11.71% of Crinetics Pharmaceuticals' shares are currently sold short. Learn More on Crinetics Pharmaceuticals' current short interest. What is a good short interest ratio for Crinetics Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CRNX shares currently have a short interest ratio of 11.0. Learn More on Crinetics Pharmaceuticals's short interest ratio. Which institutional investors are shorting Crinetics Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Crinetics Pharmaceuticals: Caption Management LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Crinetics Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.71% of Crinetics Pharmaceuticals' floating shares are currently sold short. Is Crinetics Pharmaceuticals' short interest increasing or decreasing? Crinetics Pharmaceuticals saw a increase in short interest in May. As of May 31st, there was short interest totaling 10,210,000 shares, an increase of 0.5% from the previous total of 10,160,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Crinetics Pharmaceuticals' short interest compare to its competitors? 11.71% of Crinetics Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Crinetics Pharmaceuticals: Ascendis Pharma A/S (9.28%), Moderna, Inc. (19.23%), Viatris Inc. (4.33%), Qiagen (2.96%), Blueprint Medicines Co. (9.93%), Roivant Sciences Ltd. (10.63%), Revolution Medicines, Inc. (11.86%), Verona Pharma plc (9.37%), BridgeBio Pharma, Inc. (15.35%), Elanco Animal Health Incorporated (5.32%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), Strategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks. What does it mean to sell short Crinetics Pharmaceuticals stock? Short selling CRNX is an investing strategy that aims to generate trading profit from Crinetics Pharmaceuticals as its price is falling. CRNX shares are trading down $0.75 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Crinetics Pharmaceuticals? A short squeeze for Crinetics Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CRNX, which in turn drives the price of the stock up even further. How often is Crinetics Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRNX, twice per month. The most recent reporting period available is May, 31 2025. More Short Interest Resources from MarketBeat Related Companies Ascendis Pharma A/S Short Interest Data Moderna Short Interest Data Viatris Short Interest Data Qiagen Short Interest Data Blueprint Medicines Short Interest Data Roivant Sciences Short Interest Data Revolution Medicines Short Interest Data Verona Pharma Short Interest Data BridgeBio Pharma Short Interest Data Elanco Animal Health Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CRNX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored2025 Market Crash50-Year Legend: Here's The Day Stocks Likely Crash Investing legend finds best cycle indicator during 50-ye...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.